Impact of combined treatment with rosuvastatin and antidepressants on liver and kidney function in rats

Herbet,Mariola; Gawrońska‑Grzywacz,Monika; Izdebska,Magdalena; Piątkowska‑Chmiel,Iwona; Jagiełło‑Wójtowicz,Ewa

doi:10.3892/etm.2016.3068

Impact of combined treatment with rosuvastatin and antidepressants on liver and kidney function in rats

Authors:
- Mariola Herbet
- Monika Gawrońska‑Grzywacz
- Magdalena Izdebska
- Iwona Piątkowska‑Chmiel
- Ewa Jagiełło‑Wójtowicz
View Affiliations

Affiliations: Chair and Department of Toxicology, Medical University of Lublin, Lublin 20‑093, Poland
Published online on: February 10, 2016 https://doi.org/10.3892/etm.2016.3068
Pages: 1459-1464

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Depression is among the most prevalent and life-threatening forms of mental illness, and is also a risk factor for cardiovascular disorders, diabetes and metabolic syndrome. Elderly patients commonly receive statins for the prevention of cardiovascular diseases, and antidepressant drugs for the treatment of depression. It should be noted that long‑term polypharmacotherapy may lead to potential drug interactions and disorders of the organs. The aim of the present study was to determine whether, and to what extent, combined treatment with rosuvastatin and antidepressants (amitriptyline or fluoxetine) influences the biochemical markers of liver and kidney function in a rat model. For this purpose, the activity levels of aspartate aminotransferase, alanine aminotransferase (ALT), γ‑glutamyltransferase (GGT) and the concentrations of total protein, urea, creatinine and β2‑microglobulin were determined. The results of the study indicated that combined treatment with rosuvastatin and the antidepressants amitriptyline and fluoxetine for 14 days altered the activity levels of ALT and GGT, and the concentrations of urea and creatinine in the serum compared with groups of rats receiving rosuvastatin or either antidepressant alone. These observed changes in biochemical parameters may suggest the possibility of impaired liver and kidney function during the continuous combined exposure to the drugs. However, further clinical and animal studies are required in order to further elucidate this process.

View Figures

View References

1	Elderon L and Whooley MA: Depression and Cardiovascular Disease. Prog Cardiovasc Dis. 55:511–523. 2013. View Article : Google Scholar : PubMed/NCBI
2	Rugulies R: Depression as a predictor for coronary heart disease. A review and meta-analysis. Am J Prev Med. 23:51–61. 2002. View Article : Google Scholar : PubMed/NCBI
3	Ramasubbu R and Patten SB: Effect of depression on stroke morbidity and mortality. Can J Psychiatry. 48:250–257. 2003.PubMed/NCBI
4	Luvai A, Mbagaya W, Hall AS and Barth JH: Rosuvastatin: A review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin Med Insights Cardiol. 6:17–33. 2012.PubMed/NCBI
5	You H, Lu W, Zhao S, Hu Z and Zhang J: The relationship between statins and depression: A review of the literature. Expert Opin Pharmacother. 14:1467–1476. 2013. View Article : Google Scholar : PubMed/NCBI
6	Guthrie RM and Martin DR: The safety of rosuvastatin: Effect of renal and hepatic function. Expert Opin Drug Saf. 6:573–581. 2007. View Article : Google Scholar : PubMed/NCBI
7	Chan KL, Dumesnil JG, Tam J, Ni A and Teo K: Effect of rosuvastatin on C-reactive protein and progression of aortic stenosis. Am Heart J. 161:1133–1139. 2011. View Article : Google Scholar : PubMed/NCBI
8	Cohen DE, Anania FA and Chalasani N: National Lipid Association Statin Safety Task Force Liver Expert Panel: An assessment of statin safety by hepatologists. Am J Cardiol. 97:77C–81C. 2006. View Article : Google Scholar : PubMed/NCBI
9	Soran H and Durrington P: Rosuvastatin: Efficacy, safety and clinical effectiveness. Expert Opin Pharmacother. 9:2145–2160. 2008. View Article : Google Scholar : PubMed/NCBI
10	Jian W and Davidson JR: Antidepressant therapy in patients with ischemic heart disease. Am Heart J. 150:871–881. 2005. View Article : Google Scholar : PubMed/NCBI
11	Leucht C, Huhn M and Leucht S: Amitriptyline versus placebo for major depressive disorder. Cochrane Database Syst Rev. 12:CD0091382012.PubMed/NCBI
12	von Moltke LL, Greenblatt DJ and Shader RI: Clinical pharmacokinetics of antidepressants in the elderly. Therapeutic implications. Clin Pharmacokinet. 24:141–160. 1993. View Article : Google Scholar : PubMed/NCBI
13	Roose SP, Glassman AH, Attia E, Woodring S, Giardina EG and Bigger JT Jr: Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry. 155:660–665. 1998. View Article : Google Scholar : PubMed/NCBI
14	Brambilla P, Cipriani A, Hotopf M and Barbui C: Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: A meta-analysis of clinical trial data. Pharmacopsychiatry. 38:69–77. 2005. View Article : Google Scholar : PubMed/NCBI
15	Castiella A and Arenas J: Fluoxetine hepatotoxicity. Am J Gastroenterol. 89:458–459. 1994.PubMed/NCBI
16	Inkielewicz-Stępniak I: Impact of fluoxetine on liver damage in rats. Pharmacol Rep. 63:441–447. 2011. View Article : Google Scholar : PubMed/NCBI
17	Mavrides N and Nemeroff C: Treatment of depression in cardiovascular disease. Depress Anxiety. 30:328–341. 2013. View Article : Google Scholar : PubMed/NCBI
18	Herbet M, Gawrońska-Grzywacz M and Jagiełło-Wójtowicz E: The influence of combined treatment of simvastatin and amitriptyline on some biochemical parameters in rat serum. Ann UMCS Sect DDD. 23:121–127. 2010.
19	Herbet M, Gawrońska-Grzywacz M, Kwiatek K and Jagiełło-Wójtowicz E: Evaluation of selected biochemical parameters in the serum of rats pretreated with simvastatin, doxepin or their combination. Ann UMCS Sect DDD. 24:107–113. 2011.
20	Karnik NS and Maldonaldo JR: Antidepressant and statin interactions: A review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis. Psychosomatics. 46:565–568. 2005. View Article : Google Scholar : PubMed/NCBI
21	Kasiske BL, Wanner C and O'Neill WC: An Assessment of statin safety by nephrologists. Am J Cardiol. 97:82C–85C. 2006. View Article : Google Scholar : PubMed/NCBI
22	Levy NB, Blumenfield M, Beasley CM Jr, Dubey AK, Solomon RJ, Todd R, Goodman A and Bergstrom RR: Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function. Gen Hosp Psychiatry. 18:8–13. 1996. View Article : Google Scholar : PubMed/NCBI
23	Blumenfield M, Levy NB, Spinowitz B, Charytan C, Beasley CM Jr, Dubey AK, Solomon RJ, Todd R, Goodman A and Bergstrom RF: Fluoxetine in depressed patients on dialysis. Int J Psychiatry Med. 27:71–80. 1997. View Article : Google Scholar : PubMed/NCBI
24	Vasudevan AR, Hamirani YS and Jones PH: Safety of statins: Effects on muscle and the liver. Cleve Clin J Med. 72:990–993. 2005. View Article : Google Scholar : PubMed/NCBI
25	Zhang LS, Liu ZX, Lü W and Hu XY: Effects of statins on the liver: Clinical analysis of patients with ischemic stroke. Chin Med J (Engl). 124:897–900. 2011.PubMed/NCBI
26	Wille SM, Cooreman SG, Neels HM and Lambert WE: Relevant issues in the monitoring and the toxicology of antidepressants. Crit Rev Clin Lab Sci. 45:25–89. 2008. View Article : Google Scholar : PubMed/NCBI
27	Wen B, Ma L and Zhu M: Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 173:59–67. 2008. View Article : Google Scholar : PubMed/NCBI
28	Apella D, Bruguera M, Figueras A and Laporte J: Fluoxetine-induced hepatitis: Why is postmarketing surveillance needed? Eur J Clin Pharmacol. 55:545–546. 1999. View Article : Google Scholar : PubMed/NCBI
29	Mandrioli R, Forti GC and Raggi MA: Fluoxetine metabolism and pharmacological interactions: The role of cytochrome P450. Curr Drug Metab. 7:127–133. 2006. View Article : Google Scholar : PubMed/NCBI